Genmab Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
3,244
- Stock Symbol
-
GMAB
- Investments
-
6
- Share Price
-
$508.98
- (As of Friday Closing)
Genmab General Information
Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Contact Information
Website
www.genmab.comCorporate Office
- Carl Jacobsens Vej 30
- 2500 Valby
- Denmark
Corporate Office
- Carl Jacobsens Vej 30
- 2500 Valby
- Denmark
Genmab Timeline
Genmab Stock Performance
As of 20-Nov-2026, Genmab’s stock price is $508.98. Its current market cap is $31.4B with 61.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $508.98 | $513.27 | $235.11 - $590.49 | $31.4B | 61.7M | 158K | $11.91 |
Genmab Financials Summary
As of 30-Sep-2026, Genmab has a trailing 12-month revenue of $4.3B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 25,599,225 | 16,396,305 | 10,972,474 | 16,931,427 |
| Revenue | 4,296,000 | 3,720,000 | 3,121,000 | 2,390,000 |
| EBITDA | 1,135,000 | 1,198,000 | 1,260,000 | 728,000 |
| Net Income | 729,000 | 963,000 | 1,133,000 | 631,000 |
| Total Assets | 12,936,000 | 12,873,000 | 6,414,000 | 5,232,000 |
| Total Debt | 5,198,000 | 5,426,000 | 144,000 | 114,000 |
Genmab Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genmab Comparisons
Industry
Financing
Details
Genmab Competitors (74)
One of Genmab’s 74 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Symphogen | Formerly VC-backed | Ballerup, Denmark |
Genmab Patents
Genmab Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026207043-A1 | Cancer treatment with an antibody drug conjugate | Pending | 25-Mar-2025 | ||
| WO-2025242827-A1 | Bispecific antibody against pd-l1 and cd137 in combination therapy | Pending | 22-May-2024 | ||
| EP-4644413-A1 | Binding agents having altered fc-mediated effector functions | Pending | 03-May-2024 | ||
| WO-2025228844-A1 | Binding agents having altered fc-mediated effector functions | Pending | 03-May-2024 | ||
| WO-2025228542-A1 | Method for co-expression of a plurality of antibodies | Pending | 03-May-2024 | C07K16/00 |
Genmab Signals
Genmab Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Genmab Investments & Acquisitions (6)
Genmab’s most recent deal was a Merger/Acquisition with Merus for . The deal was made on 12-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Merus | 12-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| ProfoundBio | 21-May-2024 | Merger/Acquisition | Drug Discovery | ||
| CureVac | 21-Jul-2020 | Later Stage VC | Drug Discovery | ||
| iDD Biotech (antibody assets) | 18-Mar-2015 | Corporate Asset Purchase | Buildings and Property | ||
| PDL BioPharma (Antibody Manufacturing Facility Located in Brooklyn Park, Minnesota) | 13-Mar-2008 | Corporate Asset Purchase | Buildings and Property |
Genmab ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
23.4 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Genmab Exits (2)
Genmab’s most recent exit was on 21-Jul-2020 from CureVac. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| CureVac | 21-Jul-2020 | Completed |
|
||
| Paradigm Therapeutics. | 09-Dec-2002 | Early Stage VC | Completed |
|
Genmab Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Merus | Utrecht, Netherlands | 2003 |
Genmab FAQs
-
When was Genmab founded?
Genmab was founded in 1999.
-
Where is Genmab headquartered?
Genmab is headquartered in Valby, Denmark.
-
What is the size of Genmab?
Genmab has 3,244 total employees.
-
What industry is Genmab in?
Genmab’s primary industry is Biotechnology.
-
Is Genmab a private or public company?
Genmab is a Public company.
-
What is Genmab’s stock symbol?
The ticker symbol for Genmab is GMAB.
-
What is the current stock price of Genmab?
As of 20-Nov-2026 the stock price of Genmab is $508.98.
-
What is the current market cap of Genmab?
The current market capitalization of Genmab is $31.4B.
-
What is Genmab’s current revenue?
The trailing twelve month revenue for Genmab is $4.3B.
-
Who are Genmab’s competitors?
Arcus Biosciences, Vor Biopharma, Adaptimmune Therapeutics, Alector, and Symphogen are some of the 74 competitors of Genmab.
-
What is Genmab’s annual earnings per share (EPS)?
Genmab’s EPS for 12 months was $11.91.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process